| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
209.90(M) |
| Last
Volume: |
2,201,087 |
Avg
Vol: |
2,290,588 |
| 52
Week Range: |
$0.449 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
105,765 |
142,418 |
224,760 |
560,568 |
| Total Sell Value |
$175,994 |
$200,918 |
$253,717 |
$1,308,011 |
| Total People Sold |
5 |
5 |
7 |
10 |
| Total Sell Transactions |
5 |
8 |
16 |
38 |
| End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kuebler Christopher A |
Director |
– • – |
2016-09-16 |
4 |
AS |
$19.13 |
$143,475 |
D/D |
(7,500) |
27,500 |
|
- |
|
| Kuebler Christopher A |
Director |
– • – |
2016-09-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
35,000 |
|
- |
|
| Krivulka Joseph J |
Director |
– • – |
2016-09-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
50,000 |
|
- |
|
| Winger Dennis L |
Director |
– • – |
2016-09-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
26,250 |
|
- |
|
| Whitfield Roy A |
Director |
– • – |
2016-09-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
30,000 |
|
- |
|
| Lingnau Lutz |
Director |
– • – |
2016-09-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
22,450 |
|
- |
|
| Lingnau Lutz |
Director |
– • – |
2016-09-15 |
4 |
AS |
$19.06 |
$171,540 |
D/D |
(9,000) |
7,450 |
|
- |
|
| Chess Robert |
Director |
– • – |
2016-09-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
263,623 |
|
- |
|
| Chess Robert |
Director |
– • – |
2016-09-15 |
4 |
AS |
$19.21 |
$230,520 |
D/D |
(12,000) |
248,623 |
|
- |
|
| Greer R Scott |
Director |
– • – |
2016-09-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
98,333 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2016-09-01 |
4 |
AS |
$17.83 |
$1,560,125 |
D/D |
(87,500) |
128,886 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2016-09-01 |
4 |
OE |
$4.65 |
$406,875 |
D/D |
87,500 |
216,366 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2016-08-16 |
4 |
S |
$17.56 |
$58,247 |
D/D |
(3,317) |
121,980 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2016-08-16 |
4 |
S |
$17.56 |
$69,731 |
D/D |
(3,971) |
44,088 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2016-08-16 |
4 |
S |
$17.56 |
$207,507 |
D/D |
(11,817) |
128,866 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2016-08-16 |
4 |
S |
$17.56 |
$58,036 |
D/D |
(3,305) |
51,997 |
|
- |
|
| Gergel Ivan |
SVP & Chief Medical Officer |
• – – |
2016-08-16 |
4 |
S |
$17.56 |
$29,589 |
D/D |
(1,685) |
27,327 |
|
- |
|
| Labrucherie Gil M |
SVP & Chief Financial Officer |
• – – |
2016-08-16 |
4 |
S |
$17.56 |
$58,036 |
D/D |
(3,305) |
52,783 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2016-08-16 |
4 |
S |
$17.56 |
$23,460 |
D/D |
(1,336) |
18,935 |
|
- |
|
| Chess Robert |
Director |
– • – |
2016-08-01 |
4 |
AS |
$17.26 |
$86,300 |
D/D |
(5,000) |
260,623 |
|
- |
|
| Chess Robert |
Director |
– • – |
2016-08-01 |
4 |
OE |
$5.15 |
$25,750 |
D/D |
5,000 |
265,623 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2016-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
11,521 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2016-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
29,309 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2016-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
67,500 |
84,843 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2016-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
32,735 |
|
- |
|
709 Records found
|
|
Page 23 of 29 |
|
|
0.01 (0.86%) 
